E-LIB Suche - Ergebnisse für: Salkeni, Mohamad Adham

1

Neu Perspectives, Therapies, and Challenges for Metastatic ..:

Salkeni, Mohamad Adham ; Rizvi, Wajeeha ; Hein, Kyaw.
Breast Cancer: Targets and Therapy. 13 (2021) - p. 539-557 , 2021

Link: https://doi.org/10.2147/..

2

Metastatic breast cancer: Endocrine therapy landscape resha..:

Salkeni, Mohamad Adham ; Hall, Samantha June
Avicenna Journal of Medicine. 7 (2017) 4 - p. 144-152 , 2017

Link: https://doi.org/10.4103/..

3

Neu Perspectives, Therapies, and Challenges for Metastatic ..:

Salkeni, Mohamad Adham ; Rizvi, Wajeeha ; Hein, Kyaw.
info:eu-repo/semantics/altIdentifier/doi/10.2147/BCTT.S288344. , 2021

Link: https://www.dovepress.co..

4

Safety and Efficacy of T-DM1 Plus Neratinib in Patients Wit..:

Abraham, Jame ; Montero, Albert J ; Jankowitz, Rachel C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784849/. , 2019

Link: http://www.ncbi.nlm.nih...

5

Metastatic breast cancer: Endocrine therapy landscape resha..:

Salkeni, Mohamad Adham ; Hall, Samantha June
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655644/. , 2017

Link: http://www.ncbi.nlm.nih...

6

Metastatic breast cancer: Endocrine therapy landscape resha..:

Mohamad Adham Salkeni ; Samantha June Hall
http://www.thieme-connect.de/DOI/DOI?10.4103/ajm.AJM_20_17. , 2017

Link: https://doi.org/10.4103/..

7

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab..:

Jacobs, Samuel A. ; Wang, Ying ; Abraham, Jame...
Breast Cancer Research. 26 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

8

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado..:

Jacobs, Samuel A. ; Wang, Ying ; Abraham, Jame...
Breast Cancer Research. 26 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

9

Resistance to Immunotherapy: Mechanisms and Means for Overc..:

, In: Advances in Experimental Medicine and Biology; Immunotherapy,

Salkeni, Mohamad A. ; Shin, John Y. ; Gulley, James L. - p. 45-80 , 2021

Link: https://doi.org/10.1007/..

10

The Stem Cell Phenotype of Aggressive Breast Cancer Cells:

Margaryan, Naira V. ; Hazard-Jenkins, Hannah ; Salkeni, Mohamad A....
Cancers. 11 (2019) 3 - p. 340 , 2019

Link: https://doi.org/10.3390/..

11

Prognostic factors in breast cancer patients evaluated by p..:

Farrugia, Mark ; Wen, Sinjen ; Jacobson, Geraldine.
World Journal of Nuclear Medicine. 17 (2018) 4 - p. 275-280 , 2018

Link: https://doi.org/10.4103/..

12

Randomized Phase II Study of Ramucirumab or Icrucumab in Co..:

Vahdat, Linda T. ; Layman, Rachel ; Yardley, Denise A....
The Oncologist. 22 (2017) 3 - p. 245-254 , 2017

Link: https://doi.org/10.1634/..

13

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib..:

Wise-Draper, Trisha M. ; Moorthy, Ganesh ; Salkeni, Mohamad A....
Targeted Oncology. 12 (2017) 3 - p. 323-332 , 2017

Link: https://doi.org/10.1007/..

14

Detection of EGFRvIII mutant DNA in the peripheral blood of..:

Salkeni, Mohamad A. ; Zarzour, Ahmad ; Ansay, Tracy Y....
Journal of Neuro-Oncology. 115 (2013) 1 - p. 27-35 , 2013

Link: https://doi.org/10.1007/..

15

Lipopolysaccharide Impairs Blood–Brain Barrier P-glycoprote..:

Salkeni, Mohamad A. ; Lynch, Jessica L. ; Otamis-Price, Tulin.
Journal of Neuroimmune Pharmacology. 4 (2008) 2 - p. 276-282 , 2008

Link: https://doi.org/10.1007/..